OBJECTIVE: Subcellularly localized (nuclear and/or cytoplasmic) survivin has various functions, and correlates with prognosis of malignant tumors. However, there have been no reports about the significance of subcellularly localized survivin in high-grade astrocytomas. The aim of the present study was to examine the relationship between prognosis and subcellular localization of survivin in high-grade astrocytoma. METHODS: We immunohistochemically examined the pattern of subcellular localization of survivin expression (nuclear, cytoplasmic, or both) in 51 patients with high-grade astrocytoma (19 anaplastic astrocytomas; 32 glioblastomas). We statistically examined the relationship between survivin localization and prognosis, using multivariate analysis including other clinicopathological factors (age, sex, WHO grade, extent of resection, MIB-1 labeling index, and expression of p53 and epidermal growth factor receptor). RESULTS: All specimens stained positive for survivin: localized in nucleus only (nuclear-positive group), 10 cases (20%); localized in cytoplasm only (cytoplasmic-positive group), 23 cases (45%); simultaneous expression in nucleus and cytoplasm (nuclear-cytoplasmic group), 19 cases (35%). There was no significant difference in prognosis between the nuclear-positive group and cytoplasmic-positive group (P=0.796). However, the nuclear-cytoplasmic group had significantly shorter overall survival than the nuclear-positive group and the cytoplasmic-positive group (P<0.0001). CONCLUSIONS: We found that simultaneous expression of survivin in both the nucleus and cytoplasm is an important prognostic factor for high-grade astrocytoma. The present findings indicate that subcellular localization of survivin expression is a reliable prognostic factor for patients with this tumor.
OBJECTIVE: Subcellularly localized (nuclear and/or cytoplasmic) survivin has various functions, and correlates with prognosis of malignant tumors. However, there have been no reports about the significance of subcellularly localized survivin in high-grade astrocytomas. The aim of the present study was to examine the relationship between prognosis and subcellular localization of survivin in high-grade astrocytoma. METHODS: We immunohistochemically examined the pattern of subcellular localization of survivin expression (nuclear, cytoplasmic, or both) in 51 patients with high-grade astrocytoma (19 anaplastic astrocytomas; 32 glioblastomas). We statistically examined the relationship between survivin localization and prognosis, using multivariate analysis including other clinicopathological factors (age, sex, WHO grade, extent of resection, MIB-1 labeling index, and expression of p53 and epidermal growth factor receptor). RESULTS: All specimens stained positive for survivin: localized in nucleus only (nuclear-positive group), 10 cases (20%); localized in cytoplasm only (cytoplasmic-positive group), 23 cases (45%); simultaneous expression in nucleus and cytoplasm (nuclear-cytoplasmic group), 19 cases (35%). There was no significant difference in prognosis between the nuclear-positive group and cytoplasmic-positive group (P=0.796). However, the nuclear-cytoplasmic group had significantly shorter overall survival than the nuclear-positive group and the cytoplasmic-positive group (P<0.0001). CONCLUSIONS: We found that simultaneous expression of survivin in both the nucleus and cytoplasm is an important prognostic factor for high-grade astrocytoma. The present findings indicate that subcellular localization of survivin expression is a reliable prognostic factor for patients with this tumor.
Authors: Jose A Rodríguez; Simone W Span; Carlos G M Ferreira; Frank A E Kruyt; Giuseppe Giaccone Journal: Exp Cell Res Date: 2002-04-15 Impact factor: 3.905
Authors: Whitney Salz; Dan Eisenberg; Janet Plescia; David S Garlick; Robert M Weiss; Xue-Ru Wu; Tung-Tien Sun; Dario C Altieri Journal: Cancer Res Date: 2005-05-01 Impact factor: 12.701
Authors: Hugo Caldas; Yuying Jiang; Michael P Holloway; Jason Fangusaro; Csaba Mahotka; Edward M Conway; Rachel A Altura Journal: Oncogene Date: 2005-03-17 Impact factor: 9.867
Authors: Ellen J Schlette; L Jeffrey Medeiros; Andre Goy; Raymond Lai; George Z Rassidakis Journal: J Clin Oncol Date: 2004-05-01 Impact factor: 44.544
Authors: P Grabowski; T Kühnel; F Mühr-Wilkenshoff; B Heine; H Stein; M Höpfner; C T Germer; H Scherübl Journal: Br J Cancer Date: 2003-01-13 Impact factor: 7.640
Authors: Roberta Soares Faccion; Regina Moreira Ferreira; Marília Fornaciari Grabois; Theresinha Carvalho Fonseca; Jose Antonio de Oliveira; Raquel Ciuvalschi Maia Journal: Pathol Oncol Res Date: 2011-06-17 Impact factor: 3.201
Authors: D J Morrison; L E Hogan; G Condos; T Bhatla; N Germino; N P Moskowitz; L Lee; D Bhojwani; T M Horton; I Belitskaya-Levy; L M Greenberger; I D Horak; S A Grupp; D T Teachey; E A Raetz; W L Carroll Journal: Leukemia Date: 2011-08-16 Impact factor: 11.528
Authors: T Saito; S Hama; H Izumi; F Yamasaki; Y Kajiwara; S Matsuura; K Morishima; T Hidaka; P Shrestha; K Sugiyama; K Kurisu Journal: Br J Cancer Date: 2008-01-15 Impact factor: 7.640